B7-33 Overview
Category:
Research peptide analogue of relaxin-2 (RXFP1 agonist)
How It Works:
Selectively activates the relaxin family peptide receptor 1 (RXFP1), triggering antifibrotic and tissue-protective pathways (ERK1/2 phosphorylation and extracellular matrix remodeling) while minimizing hormonal cAMP pathways associated with reproductive signaling.
Alternative Names:
B-chain relaxin analog, RXFP1-selective peptide
Primary Research Focus:
- Fibrosis prevention
- Cardiovascular remodeling
- Vascular and organ repair pathways
Potential Risks:
Limited clinical human data; largely studied in animal models; long-term effects unknown.
What It Is
B7-33 is a synthetic peptide derived from the B-chain of human relaxin-2 designed to mimic some of the tissue-protective actions of the native hormone, particularly anti-fibrotic and vasoprotective effects, while avoiding certain hormonal effects tied to the full relaxin protein.
Relaxin-2 (serelaxin) naturally plays roles in cardiovascular adaptations, extracellular matrix modulation, and vasodilation. B7-33 retains selectivity for the RXFP1 receptor to drive beneficial signaling pathways believed to be relevant for fibrosis and tissue remodeling research.
How It Works in the Body
Selective Receptor Activation
B7-33 binds RXFP1, a G-protein-coupled receptor, initiating downstream signaling that differs from the full relaxin peptide by favoring ERK1/2 phosphorylation and matrix metalloproteinase (MMP) modulation, which are linked to collagen turnover and extracellular matrix breakdown.
Anti-Fibrotic and Remodeling Pathways
Preclinical work suggests that B7-33 may reduce fibrosis and scar tissue formation by stimulating pathways that increase collagen-degrading enzymes (like MMPs) and modulate fibroblast activity.
Vascular Support and Cardioprotection
In animal models, B7-33 has shown vasodilatory and cardioprotective effects, preserving heart function after induced ischemic injury and supporting endothelial health, potentially mirroring the benefits of relaxin-2 but with distinct signaling emphasis.
B7-33 Benefits
Anti-Fibrotic Action
Research indicates that B7-33 reduces excessive collagen accumulation and fibrosis in tissues such as the heart, lungs, and kidneys by modulating extracellular matrix pathways and increasing activity of collagen-degrading enzymes (MMPs) without strongly activating traditional hormonal pathways.
Cardiovascular Protection
In animal ischemia-reperfusion models, B7-33 significantly reduced infarct size and preserved cardiac function, suggesting its potential to limit adverse remodeling following myocardial injury.
Vasodilation and Circulatory Benefits
Studies comparing B7-33 with relaxin-2 showed it can enhance endothelium-dependent vasorelaxation in certain vascular beds, aiding blood flow regulation and possibly benefiting conditions like hypertension or preeclampsia models.
Cytoprotective and Anti-Inflammatory Signals
By activating protective signaling pathways, B7-33 may reduce cellular stress responses (e.g., in heart cells exposed to ischemic stress) and mitigate pro-inflammatory signaling that drives tissue degradation.
Potential Organ Support
Preclinical research suggests effects extending to renal and pulmonary systems, where fibrosis and extracellular matrix dysregulation play key roles in disease progression, though robust human data is not yet available.
Clinical Studies
Currently, B7-33 research is largely preclinical, with animal studies demonstrating cardioprotective and anti-fibrotic outcomes in models of ischemic injury and implant-induced fibrosis.
To date:
- Myocardial infarction models (mice): B7-33 reduced infarct size and preserved cardiac function after injury.
- Fibrotic capsule models: B7-33 coatings on implant materials reduced fibrotic encapsulation significantly in mice, indicating potential for anti-fibrotic applications in biomaterials.
- Vascular studies (rats): B7-33 mimicked relaxin-2’s vasoprotective effects in select arteries and prevented endothelial dysfunction in experimental setups.
Human clinical trials are not widely reported in registries, and most citations refer to preclinical or mechanistic research.
Safety, Side Effects, and Considerations
Safety Profile
- Limited human data: Most evidence comes from animal and cell studies; no widespread human clinical safety database exists.
- Minimal hormonal activity: Because B7-33 selectively favors antifibrotic signaling over the reproductive cAMP pathway, it is theorized to reduce potential hormonal side effects compared with full relaxin-2 analogues.
Potential Side Effects
- Unknown in humans: Without controlled human trials, side effects are speculative and based on mechanism (e.g., hypotension or vascular effects from vasodilation).
- Injection reactions: Animal studies use injections; in research settings, local site reactions are possible.
Research Considerations
- Experimental status: B7-33 remains an investigational peptide. Its use is confined to laboratory research and academic studies.
- Quality and sourcing: Reliable peptide synthesis and rigorous experimental protocols are critical to ensure reproducible results.
Bottom Line:
B7-33 is a promising relaxin-based peptide analogue with anti-fibrotic, cardioprotective, and vasoprotective research signals in animal models. It remains primarily a preclinical research focus, with human clinical evidence still required to confirm safety, efficacy, and therapeutic potential.
